Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS. Gane EJ, et al. Among authors: smith p. Antimicrob Agents Chemother. 2014;58(2):1136-45. doi: 10.1128/AAC.01515-13. Epub 2013 Dec 2. Antimicrob Agents Chemother. 2014. PMID: 24295986 Free PMC article. Clinical Trial.
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Le Pogam S, Yan JM, Chhabra M, Ilnicka M, Kang H, Kosaka A, Ali S, Chin DJ, Shulman NS, Smith P, Klumpp K, Nájera I. Le Pogam S, et al. Among authors: smith p. Antimicrob Agents Chemother. 2012 Nov;56(11):5494-502. doi: 10.1128/AAC.01035-12. Epub 2012 Aug 6. Antimicrob Agents Chemother. 2012. PMID: 22869576 Free PMC article. Clinical Trial.
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Zhou J, Yetzer ES, Ballester R, Dwyer C, Tong X, Nájera I, Bertasso A, Hammond J, Kindrick A, Morcos PN, Smith P, Stancic S, Shulman NS. Gane EJ, et al. Among authors: smith p. Liver Int. 2015 Jan;35(1):79-89. doi: 10.1111/liv.12588. Epub 2014 Jun 19. Liver Int. 2015. PMID: 24814388 Clinical Trial.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. Lim SR, et al. Among authors: smith p. Antimicrob Agents Chemother. 2012 Jan;56(1):271-9. doi: 10.1128/AAC.05636-11. Epub 2011 Nov 7. Antimicrob Agents Chemother. 2012. PMID: 22064535 Free PMC article. Clinical Trial.
13,163 results
You have reached the last available page of results. Please see the User Guide for more information.